Searched for
GILEAD SCIENCES INC
Gilead Sciences Inc (GILD) share price, Expedia Group Inc (EXPE) stocks make record-breaking jump. Details hereUS Stock Market indexes S&P 500, Nasdaq, and Dow Jones made weekly gains as Gilead Sciences Inc (GILD) and Expedia Group Inc (EXPE) stocks ...- WHO defends data after concluding Gilead's remdesivir flopped COVID-19 trialGilead has questioned the findings that concluded remdesivir does not help patients who have been admitted to hospital, saying the "emergin...
- Gilead nears deal to buy Immunomedics for more than $20 billion: ReportA deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer ca...
- India's shortage of remdesivir is easing, Goa plant to ramp up production: CiplaRemdesivir, made by U.S.-based Gilead Sciences Inc, has been in high demand globally, and a handful of companies including Cipla are author...
- India's Zydus Cadila to make Gilead's potential COVID-19 drug remdesivirZydus, listed as Cadila Healthcare, joins other Indian pharmaceutical companies Cipla Ltd, Jubilant Sciences Ltd and privately held Hetero ...
- Gilead under gun to mass-produce virus drug or risk exclusivityAll of that could add up to market wins if remdesivir lives up to expectations and Gilead can ramp up to sufficiently respond to Covid-driv...
- Gilead's antiviral drug remdesivir flops in first trialThe Chinese trial showed the antiviral remdesivir did not improve patients' condition or reduce the pathogen's presence in the bloodstream,...
- Gilead to buy Kite for $11.9 billion in cancer drug megadealWith Kite, Gilead will gain cancer therapies and experimental drugs in one of the most promising fields in oncology, in addition to its hep...
- Natco settles patent suit with Gilead, others over TamifluNatco Pharma and its partner Alvogen today said they have settled patent infringement suit with Gilead Sciences Inc and others over Tamiflu.
- Dr Reddy's to launch Hepatitis C drug in IndiaSofosbuvir is a medicine used for chronic Hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.
- Zydus Cadila launches Gilead's Hepatitis C drug in IndiaSofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc, under its brand Sovaldi.
- Natco Pharma ties up with Gilead on hepatitis C drugsNatco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead, the company said.
- Strides Arcolab inks pact with Gilead Sciences for HIV drugStrides has entered into a licensing agreement with Gilead to manufacture and distribute latter's low-cost TAF used for HIV treatment in de...
- Gilead to challenge hepatitis C drug patent rejection decision"The main patent applications covering sofosbuvir are still pending before the Indian Patent Office," Alton said.
- Gilead's hepatitis C drug licensing to benefit more patients: SitharamanA delegation of Gilead Sciences Inc yesterday met Commerce and Industry Minister Nirmala Sitharaman and informed about the signing of non-e...
- CCI rules out case against Gilead SciencesCCI has rejected a complaint against Gilead Sciences Inc that alleged the US-based pharmaceutical company of abusing its dominant position.
- Strides Arcolab inks pact with Gilead Sciences to promote HIV drugStrides has inked a pact with Gilead Sciences Inc to sell low-cost generic versions of latter's HIV medicine 'emtricitabine' in developing ...
- Ranbaxy inks pact with Gilead for three generic HIV/AIDS drugsRanbaxy has entered into an agreement with US-headquartered Gilead Sciences to manufacture and market three new generic HIV/AIDS drugs.
- Aids drug prices to fall if Gilead fails to defend patent applicationPrice of a crucial AIDS drug may fall further if Cipla and AIDS patients succeed in their challenge to a patent application filed here by U...
- Ranbaxy in pact with Gilead for 'Tenofovir'Ranbaxy Laboratories Ltd said on Monday that it has entered into a licensing agreement with US-based Gilead Sciences Inc for manufacturing ...
Load More
